“Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s727. doi:10.25251/evafb145.